Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5562-5572

  Friboulet, Luc ^a,d   Barrios Gonzales, Daniel ^a,b,d   Commo, Frédéric ^a,d   Olaussen, Ken André ^a,d   Vagner, Stephan ^a,d   Adam, Julien ^a   Goubar, Aïcha ^a,d   Dorvault, Nicolas ^a,d   Lazar, Vladimir ^b   Job, Bastien ^b   Besse, Benjamin ^a,b,d   Validire, Pierre ^c   Girard, Philippe ^c   Lacroix, Ludovic ^a,b   Hasmats, Johanna ^e   Dufour, Fabienne ^b   André, Fabrice ^a,b,d   Soria, Jean Charles ^a,b,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IGR   (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MICRORNA;

ADULT; AGED; ARTICLE; CANCER TISSUE; COHORT ANALYSIS; DNA DAMAGE; DNA REPAIR; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 80052446021     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0790     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522-8.
3. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-25.
4. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11: 2215-21.
5. Cooper WA, O'Toole S, Boyer M, Horvath L, Mahar A. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology 2011;43:103-15.
6. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000;57:1229-35.
7. Shen Z. Genomic instability and cancer: an introduction. J Mol Cell Biol 2010;3:1-3.
8. Bergstralh DT, Sekelsky J. Interstrand crosslink repair: can XPFERCC1 be let off the hook?Trends Genet 2008;24:70-6.
9. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
10. Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 2011;178: 69-78.
11. Ozkan M, Akbudak IH, Deniz K, Dikilitas M, Dogu GG, Berk V, et al. Prognostic value of excision repair cross-complementing gene 1expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev 2010;11:181-5.
12. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007;25:5172-9.
13. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:3855-9.
14. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304.
15. Kim KH, Do IG, Kim HS, Chang MH, Kim HS, Jun HJ, et al. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. Apmis 2010;118:941-8.
16. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:902-6.
17. Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, et al. Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol 2010;97:352-9.
18. De Castro G, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 2011;25:693-9.
19. Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008;60:401-7.
20. Gandara DR, Grimminger P, Mack PC, Lara PN, Li T, Danenberg PV, et al. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 2010;5:1933-8.
21. Andrieux LO, Fautrel A, Bessard A, Guillouzo A, Baffet G, Langouet S. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res 2007;67:2114-23.
22. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003;159:439-52.
23. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289-300.
25. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair crosscomplementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-54.
26. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
27. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat 2009;19:530-42.
28. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-83.
29. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-16.
30. Powley IR, Kondrashov A, Young LA, Dobbyn HC, Hill K, Cannell IG, et al. Translational reprogramming following UVB irradiation is mediated by DNA-PKcs and allows selective recruitment to the polysomes of mRNAs encoding DNA repair enzymes. Genes Dev 2009;23:1207-20.
31. Arbogast S, Behnke S, Opitz I, Stahel RA, Seifert B, Weder W, et al. Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297. Appl Immunohistochem Mol Morphol 2010;19:99-105.
32. Sun Y, Li T, Ma K, Tian Z, Zhu Y, Chen F, et al. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Cancer Invest 2009;27:891-7.
33. Melton DW, Ketchen AM, Nunez F, Bonatti-Abbondandolo S, Abbondandolo A, Squires S, et al. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phasedependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci 1998;111(Pt 3): 395-404.
34. de Anta JM, Jassem E, Rosell R, Martínez-Roca M, Jassem J, Martínez-López E, et al. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 1997;15:2951-8.
35. Kandioler-Eckersberger D, Kappel S, Mittlbock M, Dekan G, Ludwig C, Janschek E, et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:744-50.
36. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2009;4:12-21.
37. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:2018-23.
38. Szymanowska A, Jassem E, Dziadziuszko R, Skrzypski M, Kobierska-Gulida G, Holm K, et al. Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer. Pneumonol Alergol Pol 2005;73:264-9.
39. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-57.
40. Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, Chen Z, et al. Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 2007;28:760-70.
41. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, , et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
42. Kirschner K, Melton DW. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 2010;30:3223-32.
43. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 2010;20:784-93.
44. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010;394:623-7.
45. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E. miR-375 targets 30-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008;57:2708-17.